Branded Generics are a patented drug, a novel dosage form of a generic drug with a definite trade name. The manufactures opt for this to gain profit from their customers who realize their medication has come off patent and that there are cheaper generics available.
The Branded Generics market is anticipated to grow in the forecast, owing to the factors such as increasing off patent pharmaceutical companies, entry of new market players, changing medicine practices and rising awareness of the patients.
Get PDF sample copy: https://www.theinsightpartners.com/sample/TIPRE00005554/
The global Branded Generics market is segmented on the basis of therapeutic application, distribution channel, drug class and formulation type. Based on therapeutic application the market is segmented into oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal diseases, dermatology diseases, analgesics and anti-inflammatory. Based on distribution channel the market is segmented into Hospitals pharmacies, Retail pharmacies. Online pharmacies, Drug stores. Based on drug class the market is segmented into Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptic, Others. Based on Formulation type the market is segmented into Oral, Parental, Topical, Others.
– Mylan N.V
– Teva Pharmaceutical Industries Ltd
– GlaxoSmithKline plc
– Bausch Health (Valeant Pharmaceuticals)
– Sandoz International GmbH
– Zydus Cadila
– Par Pharmaceutical
– Lupin Pharmaceuticals, Inc
– Sanofi
– AstraZeneca
– Dr. Reddy’s Laboratories Ltd